Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:45 AM
Ignite Modification Date:
2025-12-25 @ 2:45 AM
NCT ID:
NCT03831633
Eligibility Criteria:
Inclusion Criteria:
* Male or female, Age ≥ 18 years
* Have a histological or cytological confirmed solid tumor malignancy
* Patient scheduled to receive their first course of anthracycline cyclophosphamide (AC) based chemotherapy regimen or Moderately Emetogenic Chemotherapy for the treatment of solid malignant tumor
* Patient scheduled to receive CINV prevention with AKYNZEO® or Standard of Care according to the summary of product characteristics based on the judgement of their investigator's
* Naïve of CT
* ECOG performance up to 2
* Able to read, understand and follow the study procedures
* Patient with Health insurance
Exclusion Criteria:
* Pregnancy and breastfeeding women;
* Hypersensitivity to active substances, excipients or other ingredients of Akynzeo® or Emend®;
* Protected patients: majors under guardianship, tutorship or other legal protection, deprived of liberty by judicial or administrative decision
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT03831633
Study Brief:
Protocol Section:
NCT03831633